{"count":2329,"next":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1920&ordering=-end_effective","previous":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1880&ordering=-end_effective","results":[{"id":2390,"title":{"de":"Suche genetischer Faktoren in Neurotrophinen beim primären Offenwinkelglaukom","en":"Candidate Gene Analysis in Neurotrophins in Primary Open Angle Glaucoma using Haplotype Tagging Single Nucleotide Polymorphisms"},"short":"CANDIDATE GENE ANALYSIS_GLAUCOMA","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-02-01T01:00:00+01:00","begin_effective":"2011-04-01T02:00:00+02:00","end_planned":"2013-01-31T01:00:00+01:00","end_effective":"2012-03-31T02:00:00+02:00","assignment":"2011-02-04T09:28:08+01:00","program":79,"subprogram":null,"organization":14043,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2758,"title":{"de":"Body Composition and Performance: Relatives Körpergewicht österreichischer Athleten","en":"Body Composition and Performance"},"short":"Body Composition","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2012-01-01T01:00:00+01:00","begin_effective":"2012-01-01T01:00:00+01:00","end_planned":"2012-03-31T02:00:00+02:00","end_effective":"2012-03-31T02:00:00+02:00","assignment":"2012-01-19T16:37:18+01:00","program":90,"subprogram":null,"organization":14011,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[1326],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2340,"title":{"de":"Die Bedeutung des gluconeogenetischen Enzyms Phosphoenolpyruvat Carboxykinase (PEPCK) für das Tumorwachstum","en":"The role of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK) in cancer growth"},"short":"PEPCK","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-09-01T02:00:00+02:00","begin_effective":"2010-12-01T01:00:00+01:00","end_planned":"2011-12-31T01:00:00+01:00","end_effective":"2012-03-31T02:00:00+02:00","assignment":"2010-11-17T10:58:29+01:00","program":null,"subprogram":null,"organization":14087,"category":10,"type":10,"partner_function":4,"manager":57557,"contact":57557,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2340-57557-10"]},{"id":2197,"title":{"de":"Aufbau eines osteuropäisches Implantationszentrum mit angeschlossenen Rehabilitations- und Trainingszentrum","en":"Development of an Eastern European implantation center with adjacent Rehabilitation and Trainings center"},"short":"Osteuropäisches_Implantationszentrum","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-04-01T02:00:00+02:00","begin_effective":"2010-04-01T02:00:00+02:00","end_planned":"2011-02-01T01:00:00+01:00","end_effective":"2012-03-31T02:00:00+02:00","assignment":"2010-05-07T10:52:01+02:00","program":null,"subprogram":null,"organization":14043,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[457],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2567,"title":{"de":"Die Wirkung eines Konzentrates multipotenter Knochenmarkszellen auf die Knochenregeneration und die Osseointegration von Zahnimplantaten nach Sinusbodenelevation","en":"Die Wirkung eines Konzentrates multipotenter Knochenmarkszellen auf die Knochenregeneration und die Osseointegration von Zahnimplantaten nach Sinusbodenelevation"},"short":"Multipotente Knochenmarkszellen","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-03-01T01:00:00+01:00","begin_effective":"2011-09-01T02:00:00+02:00","end_planned":"2012-12-31T01:00:00+01:00","end_effective":"2012-03-30T02:00:00+02:00","assignment":"2011-09-05T17:35:08+02:00","program":null,"subprogram":null,"organization":14057,"category":10,"type":10,"partner_function":4,"manager":50792,"contact":50792,"status":2,"research":4,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2567-50792-10"]},{"id":2553,"title":{"de":"Der Einfluss von Dexamethason auf rheumatoide Synoviozyten untersucht anhand einer Gen Chip Transkriptionsanalyse","en":"The Influence of Dexamethasone on Rheumatoid Fibroblast-Like Synoviocytes based on a Gene CHip Transcription Analysis"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-09-01T02:00:00+02:00","begin_effective":"2011-08-09T02:00:00+02:00","end_planned":"2011-10-31T01:00:00+01:00","end_effective":"2012-03-30T02:00:00+02:00","assignment":"2011-08-10T10:28:02+02:00","program":null,"subprogram":null,"organization":14052,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":5,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2520,"title":{"de":"CORA-BGF 2011 Untersuchung der positiven Auswirkungen erhöhter Gravitationsbelastung auf die Kreislaufbelastbarkeit","en":"CORA-BGF 2011 Untersuchung der positiven Auswirkungen erhöhter Gravitationsbelastung auf die Kreislaufbelastbarkeit"},"short":"CORA GBF","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-07-01T02:00:00+02:00","begin_effective":"2011-07-01T02:00:00+02:00","end_planned":"2012-03-30T02:00:00+02:00","end_effective":"2012-03-30T02:00:00+02:00","assignment":"2011-07-05T14:52:27+02:00","program":null,"subprogram":null,"organization":14010,"category":10,"type":10,"partner_function":4,"manager":57932,"contact":57932,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2520-57932-10"]},{"id":2438,"title":{"de":"Genvarianten in den RAD51-, XRCC2-, XRCC3-, XPD- und XPG-Genen als Prädiktionsfaktoren für Metastasierung bei PatientInnen mit Weichteilsarkomen","en":"Genetic variants in the RAD51, XRCC2, XRCC3, XPD and XPG genes as predictors of outcome in soft tissue sarcoma patients"},"short":"SOFT TISSUE SARCOMA PATIENTS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-12-01T01:00:00+01:00","begin_effective":"2011-04-01T02:00:00+02:00","end_planned":"2011-12-01T01:00:00+01:00","end_effective":"2012-03-30T02:00:00+02:00","assignment":"2011-03-03T12:10:08+01:00","program":null,"subprogram":null,"organization":14085,"category":10,"type":10,"partner_function":4,"manager":69234,"contact":69234,"status":2,"research":5,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2438-69234-10","2438-58814-12"]},{"id":1991,"title":{"de":"Proteomic characterization of mitochondrial ion channels","en":"Proteomic characterization of mitochondrial ion channels"},"short":"mitochondrial ion channels","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-01-01T01:00:00+01:00","begin_effective":"2010-01-01T01:00:00+01:00","end_planned":"2012-03-13T01:00:00+01:00","end_effective":"2012-03-13T01:00:00+01:00","assignment":"2009-11-25T16:00:48+01:00","program":69,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"J2968-B19","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":1821,"title":{"de":"Nano-Health: Nano-Plaque-Extension","en":"Nano-Health: Nano-Plaque-Extension"},"short":"Nano-Plaque-Extension","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-01-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T13:05:25+02:00","program":null,"subprogram":"Nano-Health Verlängerung","organization":14028,"category":10,"type":10,"partner_function":2,"manager":52854,"contact":52854,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1821-52854-10"]},{"id":1732,"title":{"de":"Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]","en":"Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates"},"short":"Oxygenierung","url":null,"abstract":{"de":"Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.","en":"Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring."},"begin_planned":"2009-04-01T02:00:00+02:00","begin_effective":"2009-04-01T02:00:00+02:00","end_planned":"2011-03-31T02:00:00+02:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-01-19T12:54:11+01:00","program":79,"subprogram":null,"organization":14094,"category":10,"type":10,"partner_function":4,"manager":50907,"contact":50907,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1732-50907-10"]},{"id":2496,"title":{"de":"Einfluss mechanischer Belastung auf die Expression von Matrix Metalloproteasen in Knorpelzellen aus der kindlichen Wachstumsfuge","en":"Influence of mechanical strain on the expression of Matrix Metalloproteases in chondrocytes from the infant growth plate"},"short":"KINDLICHE WACHSTUMSFUGE","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-06-01T02:00:00+02:00","begin_effective":"2011-06-01T02:00:00+02:00","end_planned":"2011-11-30T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2011-06-10T12:21:53+02:00","program":null,"subprogram":null,"organization":14049,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":1716,"title":{"de":"Nano-Health: Nano-structured materials for drug targeting, release and imaging","en":"Nano-Health: Nano-structured materials for drug targeting, release and imaging"},"short":"NANO-HEALTH","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2011-12-31T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-01-14T14:15:30+01:00","program":null,"subprogram":"Nano-Initiative","organization":28392,"category":10,"type":10,"partner_function":2,"manager":54033,"contact":null,"status":2,"research":5,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1716-54033-10"]},{"id":1820,"title":{"de":"NANO-AS: Nano-Tox-Verlängerung","en":"NANO-AS: Nano-Tox-Verlängerung"},"short":"NANO-AS","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T12:36:34+02:00","program":null,"subprogram":"Nano-Health","organization":28394,"category":10,"type":10,"partner_function":2,"manager":53900,"contact":53900,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1820-53900-10"]},{"id":2529,"title":{"de":"Untersuchung der MMP Expression in der humanen Chordomzellinie MUG-Chor 1","en":"MMP Expression Analysis on the Human Chordoma Cell Line MUG-Chor 1"},"short":"MMP EXPRESSION ANALYSIS_CHORDOMA CELL","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-06-01T02:00:00+02:00","begin_effective":"2011-07-01T02:00:00+02:00","end_planned":"2011-10-01T02:00:00+02:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2011-07-14T11:48:32+02:00","program":null,"subprogram":null,"organization":14052,"category":10,"type":10,"partner_function":4,"manager":50696,"contact":50696,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2529-50696-10"]},{"id":1819,"title":{"de":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo","en":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo"},"short":"Nano-Health: 4D Imaging of Stem Cells","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T11:50:29+02:00","program":null,"subprogram":"Nano-Health","organization":14082,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1819-50747-12"]},{"id":2495,"title":{"de":"Bipolar affektive Erkrankung und Schwangerschaft, Geburt und Postpartum","en":"Bipolar affektive Erkrankung und Schwangerschaft, Geburt und Postpartum"},"short":"Bipolar affektive Erkrankungen","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-05-01T02:00:00+02:00","begin_effective":"2011-06-01T02:00:00+02:00","end_planned":"2011-12-31T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2011-06-10T12:18:59+02:00","program":null,"subprogram":null,"organization":29444,"category":10,"type":10,"partner_function":4,"manager":50654,"contact":50654,"status":2,"research":4,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2495-50654-10"]},{"id":2414,"title":{"de":"Rolle des enterischen Nervensystems (ENS) auf die Chemotaxis von Leukozyten in der Entzuendung","en":"Chemoattraction of leukocytes by the enteric nervous system (ENS) during inflammation"},"short":"CHEMOATTR_LEUKOCYTES_ENS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-11-01T01:00:00+01:00","begin_effective":"2011-03-01T01:00:00+01:00","end_planned":"2011-10-31T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2011-02-17T09:32:46+01:00","program":null,"subprogram":null,"organization":14022,"category":10,"type":10,"partner_function":4,"manager":56687,"contact":56687,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[530],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2414-56687-10"]},{"id":2382,"title":{"de":"INTEROZEPTION KARDIALER AKTIVITÄT, STRESS-REAKTIVITÄT UND ATOPISCHE DERMATITIS","en":"CARDIAC AWARENESS, STRESS REACTIVITY  AND ATOPIC DERMATITIS"},"short":"CARDIAC AWARE STRESS REACT ATOPIC DERMAT","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-02-01T01:00:00+01:00","begin_effective":"2011-02-01T01:00:00+01:00","end_planned":"2012-02-01T01:00:00+01:00","end_effective":"2012-02-01T01:00:00+01:00","assignment":"2011-01-19T15:03:26+01:00","program":null,"subprogram":null,"organization":29447,"category":10,"type":10,"partner_function":4,"manager":60040,"contact":60040,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2382-60040-10"]},{"id":2379,"title":{"de":"Die Bedeutung der Th9-Achse bei Psoriasis ","en":"The role of Th9 in psoriasis"},"short":"TH9_PSORIASIS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-02-01T01:00:00+01:00","begin_effective":"2011-02-01T01:00:00+01:00","end_planned":"2012-01-31T01:00:00+01:00","end_effective":"2012-01-31T01:00:00+01:00","assignment":"2011-01-17T10:12:57+01:00","program":null,"subprogram":null,"organization":14047,"category":10,"type":10,"partner_function":4,"manager":51618,"contact":51618,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[1161],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2379-51618-10"]}]}